Ganaxolone for management of seizures associated with CDKL5 deficiency disorder
Authors:
- 12 December 2022
- journal article
- editorial
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 44 (2) , 128-129
Abstract
No abstract availableFunding Information
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS100947, R21NS109687, R61NS124923)
This publication has 9 references indexed in Scilit:
- Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trialThe Lancet Neurology, 2022
- Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapyExpert Review of Neurotherapeutics, 2021
- Mechanisms of action of currently used antiseizure drugsNeuropharmacology, 2020
- CDKL5 Deficiency Disorder—A Complex Epileptic EncephalopathyBrain Sciences, 2020
- Intravenously Administered Ganaxolone Blocks Diazepam-Resistant Lithium-Pilocarpine–Induced Status Epilepticus in Rats: Comparison with AllopregnanoloneThe Journal of Pharmacology and Experimental Therapeutics, 2019
- Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for EpilepsyThe Journal of Pharmacology and Experimental Therapeutics, 2018
- Ganaxolone: A New Treatment for Neonatal SeizuresFrontiers in Cellular Neuroscience, 2017
- Molecular mechanisms of antiseizure drug activity at GABAA receptorsSeizure: European Journal of Epilepsy, 2013
- GABAA Receptors in Normal Development and Seizures: Friends or Foes?Current Neuropharmacology, 2008